Fate Therapeutics: Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients, today announced that five presentations of clinical and preclinical data from the Company's induced pluripotent stem cell (iPSC) product platform will be featured at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, being held in New Orleans, Louisiana on May 13-17, 2025.The Company has been selected to deliver an oral presentation on the translational data from its Phase 1 clinical trial of FT522, an off-the-shelf, CD19-targeted CAR NK cell product candidate, in patients with relapsed / refractory B-cell lymphoma (BCL) (NCT05950334). FT522 is the first product candidate to incorporate Alloimmune Defense Receptor (ADR) technology, which is designed to reduce or eliminate the need for administration of conditioning chemotherapy to patients receiving cell therapies. In addition, the Company will highlight preclinical data from its off-the-shelf, iPSC-derived, CAR T-cell product platform across autoimmune disease, hematological malignancy and solid tumor indications.Accepted abstracts are available on the ASGCT Annual Meeting website. Presentation details are as follows:Oral PresentationPhase 1 Translational Assessment of an Off-The-Shelf CAR NK Cell Armed with Alloimmune Defense Technology for Conditioning-free TherapySession: Innovation in Alternative Cell Therapy SourcesLocation: Room 391-392Presentation Date / Time: Saturday, May 17, 2025, 11:00 AM CTPoster PresentationsAlloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning ChemotherapyPoster Number: 758Presentation Date / Time: Tuesday, May 13, 2025, 6:00 PM CTTargeting UPAR With Multiplexed-Engineered iPSC-Derived CAR T Cells to Reverse Age- and Insult-Related Fibrotic DiseasePoster Number: 789Presentation Date / Time: Tuesday, May 13, 2025, 6:00 PM CTNext-Generation Off-the-Shelf CAR T-Cell Therapies for Conditioning-Free Treatment of a Broad Spectrum of Autoimmune Diseases and Hematologic MalignanciesPoster Number: 1259Presentation Date / Time: Wednesday, May 14, 2025, 5:30 PM CTFT836, a Novel MICA/B-targeting CAR T-cell Therapy Engineered to Eliminate the Need for Conditioning Chemotherapy with Broad Activity Across Solid Tumor IndicationsPoster Number: 1229Presentation Date / ...Full story available on Benzinga.com